Quick read: Oak Longevity is a telehealth platform offering compounded semaglutide starting at $130 per month and compounded tirzepatide starting at $199 per month. The marketing leans heavily on price. The legitimacy question is more nuanced. Compounded GLP-1 medications are not FDA-approved finished drug products, and the regulatory landscape changed in 2025 when the FDA declared the brand-name shortage over. Below is what the marketing says, what the verified facts confirm, and where I'd want clearer answers before signing up.
Disclaimer: This article is for informational and educational purposes only. It is not medical advice. GLP-1 medications, including compounded versions, are prescription drugs that should only be used under the supervision of a licensed healthcare provider. Compounded medications are not FDA-approved as finished drug products. Always discuss your full medical history with a qualified clinician before starting any prescription weight management treatment.
Who Oak Longevity Actually Is
Oak Longevity (oaklovesyou.com) markets itself as an affordable telehealth platform for GLP-1 weight loss medications. The company positions its program around three things: lower monthly cost than brand-name medications, no required video call, and free shipping on every order.
The verifiable basics check out. Oak operates a working customer service line at 1-833-366-2376 and a clinic line at 435-244-7757. The company has a public Trustpilot profile with over 50 customer reviews. Patients submit an online health intake, a licensed provider reviews it, and if approved, medication ships from a compounding pharmacy partner.
That's the foundation. Where it gets more complicated — and where most reviews of telehealth GLP-1 programs gloss over the details — is what “compounded” actually means in 2026, and whether the platform's marketing claims hold up against the regulatory reality.
What Compounded Semaglutide and Tirzepatide Actually Are
Compounded medications are prepared by licensed compounding pharmacies, typically classified as 503A (patient-specific compounding) or 503B (outsourcing facilities that manufacture larger batches under FDA inspection). Both categories are legal and regulated, but neither category produces an FDA-approved finished drug product in the way that brand-name Wegovy or Zepbound is FDA-approved.
The active pharmaceutical ingredient — semaglutide or tirzepatide — is the same molecule in both compounded and brand-name versions. That's the part the marketing emphasizes, and it's accurate. What the marketing tends to skip over is everything else: excipients, sterility validation, dose-form testing, and the broader manufacturing oversight that comes with FDA approval of a finished drug product.
The 2025 regulatory shift matters here. The FDA declared the brand-name semaglutide and tirzepatide shortages resolved in early 2025, which closed the formal regulatory pathway under which compounding pharmacies had been producing these medications at scale. Some compounding now continues under different pathways — patient-specific medical necessity, dosage-form differences, or excipient differences — but the high-volume “shortage compounding” era ended.
This is the context Oak operates in. The pricing model that made compounded GLP-1s a fraction of brand-name cost was largely built during the shortage. What that pricing means going forward, and how each platform is sourcing medication after the shortage closed, is a question worth asking any telehealth provider before signing up.
Oak Longevity Pricing: Verified Numbers
Here is what Oak publicly displays as of May 2026:
Compounded semaglutide: Starting at $130 per month. The starting price represents the lowest titration dose. Higher doses cost more, which is consistent with how every compounded GLP-1 telehealth platform structures pricing.
Compounded tirzepatide: Starting at $199 per month. Same pricing structure — lowest dose at the entry price, increasing with titration.
Promotional code: OAKNEW50 is publicly displayed on the homepage and offers $50 off the first month for new patients.
Membership fees: None. No subscription fee, no consultation fee separate from medication cost.
Shipping: Free.
For context, brand-name Wegovy lists at approximately $1,349 per month at retail, and brand-name Zepbound lists at approximately $1,519 per month at retail, according to manufacturer pricing data compiled in 2025. Insurance coverage varies dramatically and many patients pay close to list price out of pocket. Oak's headline pricing represents a meaningful difference — but the comparison is between an FDA-approved finished drug product and a compounded preparation, which is not an apples-to-apples comparison even when the active ingredient is identical.
The Provider Review Question
Oak's marketing emphasizes that no video call is required. The provider review happens after the patient completes an online health questionnaire. For some patients, that's a feature — fewer barriers to access, faster turnaround, no scheduling friction. For others, it's a flag worth weighing.
GLP-1 medications are not benign. They have a thorough side-effect profile, contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2, and they can interact with other medications. The depth of the provider review matters. Oak's customer reviews on Trustpilot include both patients who praise the responsiveness of the clinical team and patients who report wanting more clinical follow-up than they received.
Whether the no-video-call model is right for you is partly about your medical complexity and partly about what kind of clinical relationship you expect from a telehealth platform. It's worth asking before signing up: how does the provider review your eligibility, what happens if you have side effects that need clinical attention, and what is the process for dose adjustment or discontinuation.
What Customer Reviews Actually Say
Public reviews on Trustpilot, which had over 50 published reviews of Oak Longevity as of early 2026, lean positive but include the usual mix you find with any telehealth weight loss platform. The patterns are worth noting because they tell you what the experience actually looks like, not what the marketing says it looks like.
What patients consistently praise: simple application process, fast shipping, responsive customer service, pricing that comes in lower than other telehealth platforms they've tried. Several reviewers specifically mention that customer service representatives call back within minutes, which is unusual for any consumer health company.
What patients note as gaps: no anti-nausea prescription support during titration (nausea is a documented common side effect of GLP-1 medications), occasional intake form issues, and the broader question of clinical depth that comes with any no-video-call telehealth model.
One pattern that appears in multiple reviews: pricing increases as patients titrate to higher doses. A patient might start at $190 per month at the lowest dose and end up at $229 per month at a higher dose. That's not unique to Oak — every compounded GLP-1 telehealth platform prices by dose tier — but it's worth understanding before assuming the headline price is what you'll pay long-term.
How Oak Compares to the Telehealth GLP-1 Landscape
Oak is one of dozens of telehealth platforms offering compounded GLP-1 medications. The market has a pricing range, and Oak sits toward the lower end of that range for both semaglutide and tirzepatide. Whether that pricing is sustainable depends on the platform's compounding-pharmacy relationships and how the post-shortage regulatory landscape evolves.
For patients comparing options, the questions that matter beyond price are: which compounding pharmacy is dispensing the medication, what the provider review actually consists of, what the cancellation and refund policy is, and what clinical support exists if side effects or dosing questions come up between refills.
If you're newer to GLP-1 medication, my honest take is that the question isn't really “which telehealth platform is cheapest” — it's “what is the right clinical pathway for me, and which platform's clinical model matches that pathway.” For a deeper comparison of the major players, see my cheapest GLP-1 telehealth platforms comparison, which goes through Oak, TrimRx, MEDVi, and others side-by-side.
What I'd Want Clearer Before Signing Up
Three things I'd ask Oak — or any compounded GLP-1 telehealth platform — before starting:
Which compounding pharmacy fills the prescription, and what is its 503A or 503B status. Patients in Oak's Trustpilot reviews mention 503B sourcing, but I'd want that confirmed in writing before my first order. The pharmacy classification affects manufacturing oversight and the regulatory pathway under which the medication is being prepared.
What the provider does if I report a serious side effect. GLP-1 medications can cause significant gastrointestinal symptoms, and rare but serious adverse events do occur. The platform's clinical response protocol matters more than the marketing copy.
What happens to my prescription if Oak's compounding pharmacy partner changes or if regulatory pressure further restricts compounded GLP-1 access. The 2025 shortage resolution shifted the landscape, and continued shifts are possible. A platform that has a clear plan for that scenario is meaningfully different from one that doesn't.
Frequently Asked Questions About Oak Longevity
Is Oak Longevity legit?
Oak Longevity has a verifiable business presence — public phone numbers, a working website, customer reviews on Trustpilot, and operates within the standard telehealth-and-compounding-pharmacy framework. Whether it's the right legitimate option for you depends on whether compounded medication is appropriate for your situation and whether the provider review model matches your clinical expectations.
How much does Oak Longevity cost in 2026?
Compounded semaglutide starts at $130 per month, and compounded tirzepatide starts at $199 per month, with free shipping and no membership fee. The promotional code OAKNEW50 offers $50 off the first month. Pricing increases at higher titration doses, which is industry-standard for compounded GLP-1 telehealth.
Is compounded GLP-1 the same as brand-name Wegovy or Zepbound?
The active ingredient — semaglutide or tirzepatide — is the same molecule. The finished drug product is not FDA-approved in the way that brand-name versions are. That difference matters and is worth discussing with a clinician before deciding which pathway is right for you. For more detail, see my compounded semaglutide vs Wegovy comparison.
Does Oak require a video call?
No. The intake is online and the provider review is conducted asynchronously. Whether that's right for you depends on your medical complexity and how much clinical interaction you want.
Should I choose semaglutide or tirzepatide?
That's a clinical decision that depends on your weight loss goals, medical history, side-effect tolerance, and budget. Tirzepatide has shown greater average weight loss in head-to-head studies, but it's also more expensive and has a different side-effect profile. My tirzepatide vs semaglutide deep-dive walks through the actual peer-reviewed data.
What about side effects?
GLP-1 medications commonly cause gastrointestinal side effects — nausea, constipation, diarrhea — particularly during titration. Less common but more serious adverse events do occur. The full safety profile is worth understanding before starting; my GLP-1 side effects guide covers what telehealth programs sometimes underemphasize.
The Honest Bottom Line
Oak Longevity is a real telehealth company with verifiable operations, competitive pricing, and a customer base that generally rates the experience well. It's not a scam, and it's not a magic solution. It's one of many compounded GLP-1 telehealth platforms operating in a regulatory environment that shifted in 2025 and continues to evolve.
If you've already done the homework — you've talked to a clinician, you understand what compounded medication is and isn't, you've thought through whether a no-video-call model fits your situation, and you've reviewed the side-effect profile — Oak is a reasonable platform to consider for affordability. If you haven't done that homework yet, the right next step isn't picking the cheapest telehealth option. It's picking the right pathway for your situation, then comparing platforms within that pathway.
The cheapest GLP-1 telehealth platform isn't always the right one. The right one is the one whose clinical model, pricing structure, and pharmacy partnerships match what you actually need. For Oak, that's likely a patient who has already had a clinical conversation about GLP-1s, who is comfortable with compounded medication, and who values cost transparency and shipping speed over deep clinical interaction.
For everyone else — and that's most people first researching this category — the right starting point is education, not a checkout page.
Leave a Reply
You must be logged in to post a comment.